Coherus Oncology Inc. Common Stock (CHRS)

FairStock Score: 41/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable economics and a margin of safety. Coherus does not offer much of either today. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $14.3 million and net loss was $20.6 million, or diluted EPS -$0.13. Fiscal Q1 2026, ended 2026-03-31, was worse: revenue $12.3 million, net loss $38.3 million, EPS -$0.28. Those follow a strange fiscal 2025: FY2025 revenue was $42.2 million and net income $168.0 million, EPS $1.43, but fiscal Q2 2025, ended 2025-06-30, alone had net income of $297.8 million. Without that large gain, the recent operating picture is loss-making. Trailing free cash flow is -$186.0 million, and FairStock's FCF yield is -112.5% against the $165.3 million market cap at the 2026-10-13 close, so cash is going out fast. FairStock's balance-sheet and return measures show debt-to-equity 0.89, Altman Z-Score -9.92, Piotroski F-Score 4/9, ROE -178.39%, and ROCE -30.52%. At the same close, P/E is -0.86 and P/B 2.74. Fiscal Q2 2026 revenue of $14.3 million was above fiscal Q2 2025 revenue of $10.3 million, so sales are moving up, but losses remain large. Biotechnology moats come from patents, clinical data, and approved products, but these figures give no proof of pricing power or consistent cash generation. FairStock Score 41/100 and the Lynch TURNAROUND category—returned to profit after a loss within the last three years—capture a fragile turnaround. At $1.07, the market is not paying much for sales, but Graham would ask what remains for shareholders after debt and cash burn. I see speculation, not a clear value bargain.

In plain English: Coherus Oncology develops and sells cancer medicines. The business looks weak right now: recent quarterly sales were around $12 million to $14 million while it lost $20 million to $38 million. At $1.07, the price looks expensive compared with those losses and the cash it is using, even though sales are growing.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer